4/A: PLUS THERAPEUTICS CEO Amends Equity Vesting Terms
Amendment to Statement of Changes in Beneficial Ownership (Form 4/A)
PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick filed an amended Form 4 to correct the vesting schedule for his Restricted Stock Units.
Summary
- Marc H. Hedrick, Chief Executive Officer and Director of PLUS THERAPEUTICS, INC. (PSTV), filed an amendment to his Statement of Changes in Beneficial Ownership (Form 4/A).
- The amendment corrects the previously disclosed vesting terms for 1,916,168 Restricted Stock Units (RSUs) awarded on August 13, 2025.
- The RSUs will now vest over twelve quarters, in substantially equal 1/12th increments, beginning with the quarter ended September 30, 2025.
- Upon vesting, the RSUs convert into shares of Common Stock on a one-for-one basis.
- The filing also details 5,748,506 stock options granted on August 13, 2025, with an exercise price of $0.5744, which vest over four years in equal 1/48th monthly increments and expire on August 12, 2035.
Sentiment
Score: 5
Explanation: The filing is an administrative correction, which is neutral in sentiment. While the underlying equity grants are positive for executive alignment, the amendment itself is a rectification of an error.
Positives
- The filing provides clarity and accuracy regarding the vesting schedule of the CEO's Restricted Stock Units, ensuring transparent disclosure.
- The significant equity grants (5,748,506 stock options and 1,916,168 RSUs) align the Chief Executive Officer's interests with those of shareholders.
Negatives
- An administrative error in the original Form 4 filing necessitated this amendment, indicating a minor oversight in initial disclosure.
Future Outlook
The filing primarily corrects historical information and details future vesting schedules for executive equity, but does not provide broader forward-looking statements or guidance on company performance.
Industry Context
This filing is a routine executive compensation disclosure, common across publicly traded companies, and does not directly relate to broader industry trends or competitive positioning beyond the standard practice of aligning executive incentives with company performance through equity grants.
Stakeholder Impact
- Shareholders receive clarified and accurate information regarding the Chief Executive Officer's equity compensation and vesting schedules, enhancing transparency.
Next Steps
- The stock options will continue to vest over four years in equal 1/48th monthly increments.
- The Restricted Stock Units will vest over twelve quarters in substantially equal 1/12th increments, beginning with the quarter ended September 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 08/13/2025 | Date of earliest transaction for both stock options and Restricted Stock Units (RSUs). |
| 08/15/2025 | Date the original Form 4 was filed, which contained the incorrect RSU vesting terms. |
| 09/30/2025 | End of the quarter when the corrected RSU vesting begins in substantially equal 1/12th increments. |
| 10/03/2025 | Date the amended Form 4/A was signed. |
| 08/12/2035 | Expiration date for the stock options. |
Keywords
PLUS THERAPEUTICS, PSTV, SEC Form 4/A, Equity Compensation, Restricted Stock Units, Stock Options, Executive Compensation, Marc H. Hedrick, Vesting Schedule
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.